• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.
【24h】

Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.

机译：Pegfilgrastim：具有持续作用时间的粒细胞集落刺激因子。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Granulocyte colony-stimulating factors such as filgrastim (Neupogen, Amgen, Inc.) and pegfilgrastim (Neulasta, Amgen, Inc.) are frequently used in clinical practice for the prevention of chemotherapy-induced neutropenia and its potentially life-threatening complications. Due to its unique neutrophil-mediated clearance, pegfilgrastim can be administered once per chemotherapy cycle. Clinical trials have shown that a single, fixed subcutaneous dose of pegfilgrastim 6 mg is comparable in safety and efficacy to daily injections of filgrastim for decreasing the incidence of infection following myelosuppressive chemotherapy in patients with cancer. Postregistrational trials have been conducted to evaluate the use of pegfilgrastim with emerging dose-dense regimens, in myeloid cancers and for mobilisation and engraftment of autologous stem cells. Ongoing clinical trials continue to explore further potential uses for pegfilgrastim.
机译：粒细胞集落刺激因子，例如非格司亭（非格司亭（Neupogen，Amgen，Inc。）和聚吡格司亭（Neulasta，Amgen，Inc。））在临床实践中经常用于预防化学疗法诱发的中性粒细胞减少症及其可能危及生命的并发症。由于其独特的嗜中性粒细胞介导的清除作用，pegfilgrastim可以在每个化疗周期中给药一次。临床试验表明，单剂量，固定皮下剂量的pegfilgrastim 6 mg在安全性和功效上与每日注射非格司亭可降低癌症患者骨髓抑制化疗后感染的发生率相当。已进行注册后试验，以评估聚乙二醇非格司亭与新兴剂量密集型疗法在骨髓癌中以及自体干细胞的动员和移植中的应用。正在进行的临床试验继续探索吡格非司亭的其他潜在用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号